1. Home
  2. CPHI vs CANF Comparison

CPHI vs CANF Comparison

Compare CPHI & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CPHI
  • CANF
  • Stock Information
  • Founded
  • CPHI N/A
  • CANF 1994
  • Country
  • CPHI China
  • CANF Israel
  • Employees
  • CPHI N/A
  • CANF 5
  • Industry
  • CPHI Biotechnology: Pharmaceutical Preparations
  • CANF Biotechnology: Pharmaceutical Preparations
  • Sector
  • CPHI Health Care
  • CANF Health Care
  • Exchange
  • CPHI Nasdaq
  • CANF Nasdaq
  • Market Cap
  • CPHI 5.3M
  • CANF 5.0M
  • IPO Year
  • CPHI N/A
  • CANF N/A
  • Fundamental
  • Price
  • CPHI $1.56
  • CANF $0.35
  • Analyst Decision
  • CPHI
  • CANF Strong Buy
  • Analyst Count
  • CPHI 0
  • CANF 2
  • Target Price
  • CPHI N/A
  • CANF $6.75
  • AVG Volume (30 Days)
  • CPHI 8.8K
  • CANF 18.9M
  • Earning Date
  • CPHI 11-12-2025
  • CANF 11-27-2025
  • Dividend Yield
  • CPHI N/A
  • CANF N/A
  • EPS Growth
  • CPHI N/A
  • CANF N/A
  • EPS
  • CPHI N/A
  • CANF N/A
  • Revenue
  • CPHI $4,052,266.00
  • CANF $560,000.00
  • Revenue This Year
  • CPHI N/A
  • CANF N/A
  • Revenue Next Year
  • CPHI N/A
  • CANF N/A
  • P/E Ratio
  • CPHI N/A
  • CANF N/A
  • Revenue Growth
  • CPHI N/A
  • CANF N/A
  • 52 Week Low
  • CPHI $1.20
  • CANF $0.28
  • 52 Week High
  • CPHI $3.35
  • CANF $2.35
  • Technical
  • Relative Strength Index (RSI)
  • CPHI 41.82
  • CANF 37.86
  • Support Level
  • CPHI $1.46
  • CANF $0.28
  • Resistance Level
  • CPHI $1.61
  • CANF $0.62
  • Average True Range (ATR)
  • CPHI 0.07
  • CANF 0.05
  • MACD
  • CPHI 0.01
  • CANF -0.00
  • Stochastic Oscillator
  • CPHI 52.41
  • CANF 21.73

About CPHI China Pharma Holdings Inc.

China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Share on Social Networks: